DBV Technologies S.A. (DBVT) vs Electra Therapeutics (ETRA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
DBV Technologies S.A. is the larger company by market cap ($611.8 million vs $578.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DBVT | ETRA |
|---|---|---|
| Share price | $9.74 | $9.21 |
| Market cap | $611.83M | $578.08M |
| 1-day change | -0.36% | +0.55% |
| YTD return | -49.03% | — |
| 1-year return | -31.39% | — |
| 5-year return | -7.83% | — |
| EPS (TTM) | $-3.50 | $-2.65 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.19 | $15.50 |
| 52-week low | $9.64 | $8.92 |
| Distance from 52-week high | -62.82% | -40.58% |
| Analyst consensus | buy | — |
| Avg. price target upside | +296.82% | — |
| Average volume | 331.54K | 948.89K |
| Shares outstanding | 62.85M | 62.77M |
| Employees | 170 | 46 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About DBV Technologies S.A.
DBVT stock →DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 170 employees
About Electra Therapeutics
ETRA stock →Electra Therapeutics, Inc. is a clinical-stage biotechnology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 46 employees
DBVT vs ETRA FAQ
Which is bigger, DBV Technologies S.A. or Electra Therapeutics?
DBV Technologies S.A. (DBVT) is larger, with a market capitalization of $611.83M compared with $578.08M for Electra Therapeutics (ETRA).
Are DBV Technologies S.A. and Electra Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.